Evome Medical Technologies Reduces Acquisition Debt, Bolsters Management Team to Support SpaceTeck Knee and Reactive Step Trainer 2024 Product Roll-Out
Evome Medical Technologies Reduces Acquisition Debt, Bolsters Management Team to Support SpaceTeck Knee and Reactive Step Trainer 2024 Product Roll-Out
"We had a great relaunch of the new Evome at the AlphaNorth Capital event in the Bahamas last week for investors," said Mike Seckler, CEO. "It was a unique opportunity to highlight our new product strategy, which increases our addressable market significantly, as well as our plan to grow a profitable company with a new set of investors. We are moving from a low margin contract manufacturing business to a higher gross margin medical device business, and I am looking forward to building on our solid turn around at end of 2023 with a strong year in 2024."NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company") (TSXV: EVMT) announced it has reduced acquisition bank debt by $535,093 as a result of the sale of Arrowhead Medical, LLC ("Arrowhead"), originally acquired in May 2023 (see News Release dated May 16, 2023). As part of the adjustment, Arrowhead will continue to serve as the exclusive distributor of Biodex products in the Midwest United States and a further $209,171 of intercompany debt will be reduced.
紐約，2024年1月31日（環球新聞專線）——Evome Medical Technologies Inc.（ “公司”）（多倫多證券交易所股票代碼：EVMT）宣佈，由於出售Arrowhead Medical，已將收購銀行的債務減少了535,093美元，有限責任公司（“Arrowhead”），最初於 2023 年 5 月收購（參見 2023 年 5 月 16 日的新聞稿）。作爲調整的一部分，Arrowhead將繼續作爲Biodex產品在美國中西部的獨家分銷商，並將再減少209,171美元的公司間債務。
The Company continues to look to make improvements to its balance sheet as it focuses on revenue and profit growth as it prepares to launch two new products in 2024, the SpaceTek Knee, an isokinetic device co-developed with NASA, and the Reactive Step Trainer, a device designed to improve balance and reduce tripping and falling with primarily elderly patients.
該公司繼續尋求改善資產負債表，專注於收入和利潤增長，準備在2024年推出兩款新產品：SpaceTek Knee，這是一款與美國宇航局共同開發的等速設備，以及旨在改善平衡、減少主要是老年患者的絆倒和跌倒的設備Reactive Step Trainer。
As part of the new product roll out, which is targeted to increase the market for Biodex products, Mr. Carmine Tronolone has been promoted to General Manager of Biodex Production in Long Island, New York; Mr. Bill Hauer has been recently appointed Vice President of Marketing and Sales, and Cherine Pottinger-Harris will serve as Controller and Director of Finance for Biodex, and Natalia Vakhitova has retired as CFO.
作爲旨在擴大Biodex產品市場的新產品推出的一部分，Carmine Tronolone先生已被提升爲紐約長島Biodex生產總經理；比爾·豪爾先生最近被任命爲營銷和銷售副總裁，謝琳·波廷格-哈里斯將擔任Biodex的財務總監兼財務總監，納塔利婭·瓦希託娃已退休首席財務官。
"We had a great relaunch of the new Evome at the AlphaNorth Capital event in the Bahamas last week for investors," said Mike Seckler, CEO. "It was a unique opportunity to highlight our new product strategy, which increases our addressable market significantly, as well as our plan to grow a profitable company with a new set of investors. We are moving from a low margin contract manufacturing business to a higher gross margin medical device business, and I am looking forward to building on our solid turn around at end of 2023 with a strong year in 2024."
首席執行官邁克·塞克勒表示：“上週在巴哈馬舉行的AlphaNorth Capital活動上，我們爲投資者精彩地重啓了新的Evome。”“這是一個難得的機會，可以重點介紹我們的新產品戰略，這極大地增加了我們的潛在市場，以及我們利用新投資者發展一家盈利公司的計劃。我們正在從低利潤的合同製造業務轉向毛利率更高的醫療器械業務，我期待在2023年底的穩健轉機基礎上再接再厲，在2024年迎來強勁的一年。”
Pursuant to an LLC Membership Interest Purchase Agreement dated January 15, 2024, the original vendor (the "Vendor") of Arrowhead has agreed to acquire, and the Company, indirectly through a subsidiary, has agreed to sell, all of the issued and outstanding LLC membership equity interests of Arrowhead, in consideration for (i) the Vendor making a cash payment to the Company of $209,171 (ii) the Vendor returning to the Company for cancellation the 1,000,000 Class "A" non-voting common shares of the Company which were issued by the Company to the Vendor on May 16, 2023, and (iii) the termination of the obligation to issue earn-out payment shares to the Vendor pursuant to the original Stock Purchase Agreement dated May 16, 2023. At the time of the sale Arrowhead had $535,093 of debt and $209,171 of cash, and it represented 2.5% of the Company's revenue and had no impact on the Company's net income for its most recently reported quarter.
根據2024年1月15日簽訂的有限責任公司會員權益購買協議，Arrowhead的原供應商（“供應商”）已同意收購Arrowhead的所有已發行和未償還的有限責任公司會員權益interests，作爲對價（i）賣方向公司支付209,171美元（ii）賣方返回公司申請取消的現金款項，indirectly 已同意出售那個公司於2023年5月16日向賣方發行的 公司1,000,000股 “A” 類無表決權普通股，以及（iii）終止根據2023年5月16日的original 股票購買協議向賣方發行收益支付股份的義務。 在出售時，Arrowhead有535,093美元的債務和209,171美元的現金，佔公司收入的2.5％，對公司最近公佈的季度的淨收入沒有影響。
The Company also announces that it has granted an aggregate of 460,000 stock options to Mr. Tronolone, Mr. Hauer and Ms. Pottinger-Harris at an exercise price equal to the closing price of its common shares on the TSX Venture Exchange on the date hereof, vesting over three years and expiring between January 9, 2029 and January 31, 2029.
該公司還宣佈，已向特羅諾隆先生、豪爾先生和波廷格-哈里斯女士授予了總共46萬份股票期權，其行使價等於截至本文發佈之日多倫多證券交易所風險交易所普通股的收盤價，在三年內歸屬，將於2029年1月9日至2029年1月31日到期。
For more information please contact:
欲了解更多信息，請聯繫：
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: Info@evomemedical.com
邁克·塞克勒
首席執行官
電話：1 (800) 760-6826
電子郵件：Info@evomemedical.com
Additional Information
附加信息
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商（該術語在the 多倫多證券交易所風險投資交易所的policies 中定義）均不對本release 的充分性或準確性承擔責任。
Unless otherwise specified, all dollar amounts in this press release are expressed in Canadian dollars.
除非另有說明，否則本新聞稿中的所有美元金額均以加拿大元dollars 表示。
Certain statements contained in this press release constitute "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as "expects" "believes", "estimates", "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", and "anticipate", and similar expressions as they relate to the Company, including: the timing and number of products the Company intends to launch; the Company's plan to grow a profitable company with a new set of investors; the Company moving from a low margin contract manufacturing business to a higher gross margin medical device business; and the Company having a strong year in 2024. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: the Company expecting increased demand for its products at increased prices and with additional distribution agreements to result in the growth of profits in 2024; the Company's attendance at investor conferences resulting in new investors; and the Company expecting to improve its product mix by increasing sales of high-margin products compared to its lower margin manufacturing sales. The Company cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
本新聞稿中包含的某些陳述構成meaning ofthe《私人證券訴訟改革法》和適用的加拿大證券laws 中的 “前瞻性信息”。這些陳述可以be 通過使用諸如 “期望” “相信”、“估計”、“可能”、“會”、 “可以” 等前瞻性術語來識別， “應該”、“潛在”、 “會”、“尋找”、“打算”、 “計劃” 和 “預測”，以及與relateto 公司類似的表述，包括：公司打算推出產品的時間和數量啓動；公司計劃通過新的投資者發展一家盈利的公司；公司從低利潤合同製造業務轉向毛利率更高的醫療器械業務；公司在2024年表現強勁。除historical 事實陳述外，所有statementsother 都可能是前瞻性的 信息。這樣statementsreflect 公司目前對未來events 的看法和意圖，以及current 信息availableto 公司，並面臨某些風險，uncertainties 和assumptions，包括：公司預計，隨着價格上漲，對其產品的需求將增加，並將達成額外的分銷協議，從而在2024年實現利潤增長；公司出席投資者會議吸引了新的投資者；以及公司預計通過增加高利潤產品的銷售來改善其產品組合，而利潤率較低製造業銷售。該公司警告說，包含herein 的the 前瞻性陳述受重要factors 的限定，這可能會導致actual 業績與such 陳述所反映的結果存在重大差異。這些因素include 但是are 不限於general 業務和economicconditionsregions inwhich the Companyoperates；公司執行密鑰的能力priorities，includingsuccessful 完成ofacquisitions、業務 留存和 戰略計劃和吸引、發展and 留住關鍵executives；困難integrating 新收購的企業；ongoing 或者供應出現新的中斷chain，extent 和such 供應鏈中斷的範圍，以及解決問題的時機或程度or 改善such 中斷；ability 到 實施業務戰略並根據公司信息開展業務opportunities;disruptions in 或attacks（包括cyber-attacks）technology、互聯網、網絡接入或其他voiceor datacommunications 系統或服務；各類欺詐或其他行爲的evolutioncriminal 對whichthe 公司的行爲是風險的；failure 需要遵守其義務 公司或其affiliates； 對現行法律法規的變更或適用的影響；newgranting of 許可證and 許可證in 一家監管嚴格的企業；overall 很難litigation 環境，包括美國States；競爭加劇；外幣匯率變化；increasedfundingcosts 還有市場volatility 到期to 市場流動性不足和資金競爭；availability 資金andresources 用於開展業務；criticalaccounting 會計準則的估計和變更、policies、 和公司使用的方法；theoccurrence 既自然又不自然 災難性eventsand 聲稱resulting 來自此類事件；以及thoserisk 討論的因素或referred 到intheCompany 的披露documents 向美國Securities 和Exchange 委員會提交andavailable 位於www .sec.gov，還有the 證券監管機構in 肯定有provinces 的Canada 和available 在。在unexpectedmanner 中，是否有任何factor 會影響公司，還是assumptions 標的the 前瞻性information 證明不正確，實際的results 或events 可能與or 事件預測的結果materially 有所不同。Any 如此具有前瞻性informationisexpressly 根據這份警示符在其entirety 中獲得資格statement。此外，the Companydoes 不要假設responsibility 的準確性或completenessforwardinformation。The 前瞻性information 包含在本新聞稿中is 截至本報的daterelease 而且公司承諾no 有義務公開更新或修改any forward-lookinginformation，other 超出了適用的law 的要求。
譯文內容由第三人軟體翻譯。
